Table 1.
Description of SARS-CoV-2 (+) EPICC Participants Included in FLU-PRO Plus Analysis, by Vaccination Status
| Total (n = 764) |
Unvaccinated (n = 587) |
Partially Vaccinated (n = 25) |
Fully Vaccinated (n = 152) |
P Value | |
|---|---|---|---|---|---|
| Age, No. (%) | .74a | ||||
| 18–44 y | 480 (62.8) | 365 (62.2) | 18 (72.0) | 97 (63.8) | |
| 45–64 y | 219 (28.7) | 174 (29.6) | 5 (20.0) | 40 (26.3) | |
| 65+ y | 65 (8.5) | 48 (8.2) | 2 (8.0) | 15 (9.9) | |
| Sex, No. (%) | .29a | ||||
| Male | 460 (60.2) | 345 (58.8) | 15 (60.0) | 100 (65.8) | |
| Female | 304 (39.8) | 242 (41.2) | 10 (40.0) | 52 (34.2) | |
| Race, No. (%) | .01a | ||||
| White | 386 (50.5) | 276 (47.0) | 12 (48.0) | 98 (64.5) | |
| Hispanic or Latino | 203 (26.6) | 170 (29.0) | 8 (32.0) | 25 (16.4) | |
| Black | 93 (12.2) | 75 (12.8) | 1 (4.0) | 17 (11.2) | |
| Asian | 34 (4.5) | 29 (4.9) | 1 (4.0) | 4 (2.6) | |
| Other | 48 (6.3) | 37 (6.3) | 3 (12.0) | 8 (5.3) | |
| Military status, No. (%) | .13a | ||||
| Active duty | 400 (52.4) | 296 (50.4) | 17 (68.0) | 87 (57.2) | |
| Dependent | 200 (26.2) | 163 (27.8) | 6 (24.0) | 31 (20.4) | |
| Retired military | 164 (21.5) | 128 (21.8) | 2 (8.0) | 34 (22.4) | |
| Delta variant (among those with variant information), No. (%) | 115 (23.1) | 18 (5.0) | 4 (26.7) | 93 (76.2) | <.01a |
| Missing variant information, No. | 267 | 227 | 10 | 30 | |
| Days since symptom onset first FLU-PRO was completed | .31b | ||||
| Mean (SD) | 8.6 (2.9) | 8.7 (2.8) | 7.8 (3.3) | 8.4 (3.1) | |
| Days FLU-PRO was completed | .01b | ||||
| Mean (SD) | 10.2 (3.6) | 10.0 (3.7) | 10.2 (3.8) | 10.9 (3.3) | |
| Poorest physical health reported on FLU-PRO, No. (%) | <.01a | ||||
| Poor | 136 (17.8) | 121 (20.6) | 1 (4.0) | 14 (9.2) | |
| Fair | 318 (41.6) | 245 (41.7) | 13 (52.0) | 60 (39.5) | |
| Good | 211 (27.6) | 159 (27.1) | 6 (24.0) | 46 (30.3) | |
| Very good | 76 (9.9) | 49 (8.3) | 4 (16.0) | 23 (15.1) | |
| Excellent | 23 (3.0) | 13 (2.2) | 1 (4.0) | 9 (5.9) | |
| Returned to activities by last FLU-PRO Plus survey, No. (%) | 564 (73.8) | 412 (70.2) | 22 (88.0) | 130 (85.5) | <.01a |
| Returned to health by last FLU-PRO Plus survey, No. (%) | 489 (64.0) | 352 (60.0) | 21 (84.0) | 116 (76.3) | <.01a |
| Maximum scores, mean (SD) | |||||
| Total score (no senses) | 0.9 (0.6) | 0.9 (0.6) | 0.7 (0.6) | 0.7 (0.6) | <.01b |
| Total score (including senses) | 0.9 (0.6) | 0.9 (0.6) | 0.8 (0.7) | 0.7 (0.6) | <.01b |
| Throat score | 0.7 (0.9) | 0.8 (0.9) | 0.8 (1.0) | 0.6 (0.8) | .04b |
| Eyes score | 0.6 (0.8) | 0.6 (0.8) | 0.7 (0.9) | 0.5 (0.8) | .01b |
| Nose score | 1.2 (0.9) | 1.2 (0.8) | 1.1 (0.8) | 1.3 (0.9) | .45b |
| Systemic score | 1.1 (0.9) | 1.2 (0.9) | 0.8 (1.0) | 0.8 (0.8) | <.01b |
| Gastrointestinal score | 0.7 (0.7) | 0.7 (0.7) | 0.5 (0.6) | 0.4 (0.5) | <0.01b |
| Respiratory score | 1.1 (0.8) | 1.2 (0.8) | 1.0 (0.8) | 0.9 (0.8) | <0.01b |
| Senses score | 1.6 (1.6) | 1.7 (1.6) | 1.7 (1.6) | 1.4 (1.6) | .05b |
Abbreviations: EPICC, epidemiology, immunology, and clinical characteristics of pandemic infectious diseases study; FLU-PRO Plus, inFLUenza Patient-Reported Outcome Plus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Pearson’s chi-square test.
b
Kruskal-Wallis rank-sum test.